B
Biocartis
Biotech & Life Sciences · Mechelen, Belgium · Founded 2007 · IPO 2015
Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments MoreLess
Biocartis is a pioneering molecular diagnostics company dedicated to transforming molecular testing through its unique IdyllaTM platform. The company provides advanced diagnostic solutions designed to improve clinical practice for patients, clinicians, payers, and the broader healthcare industry. Biocartis operates in the molecular diagnostics market, focusing on oncology and infectious diseases. Its primary clients include hospitals, laboratories, and healthcare providers who require rapid and accurate diagnostic results. The business model revolves around the sale of diagnostic instruments and consumables, generating revenue through the continuous use of its proprietary platform and assays. Biocartis makes money by selling its IdyllaTM platform and associated diagnostic tests, which offer quick and reliable results, thereby enhancing patient care and operational efficiency in clinical settings.
Keywords: molecular diagnostics, Idylla platform, oncology, infectious diseases, clinical practice, healthcare providers, rapid testing, diagnostic solutions, proprietary technology, patient care.
Talent graph
Biocartis's talent
Source: Dealroom Talent Intelligence.
Investors
12 investors on Biocartis's cap table
Sourced from Dealroom's funding and investor records.












Global footprint
Where Biocartis has talent and traffic
team presence
across markets
Market sentiment
What the market is saying about Biocartis
An AI-synthesized read of the highest-engagement posts about Biocartis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biocartis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.